Combination treatment for lung cancer with liver spread
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of two medications (SKB264 and anlotinib) for people with advanced non-small cell lung cancer that has spread to the liver and no longer responds to a standard pill called an EGFR-TKI. The goal is to see if this combination can shrink tumors and help people live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- Your general health should be good (performance status 0-1).
- You have non-small cell lung cancer that is advanced or has spread, and it is not able to be removed by surgery or cured with radiation.
- You have at least one tumor in your liver that can be measured.
- Your lung cancer grew despite previous treatment with an EGFR-TKI pill (like erlotinib, gefitinib, or osimertinib).
- You are expected to live at least 3 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests a combination treatment to control advanced or metastatic non-small cell lung cancer (NSCLC). It is mainly for people whose tumor has specific gene features (EGFR and ALK testing results) and who are able to provide tumor tissue for biomarker testing.
This trial tests a combination of focused radiation (stereotactic radiosurgery) and an oral targeted therapy called anlotinib for people with non-small cell lung cancer that has spread to the brain. It may offer a way to control brain metastases without more invasive procedures.
This trial tests a new drug called SKB571, given in combination with other treatments, for non-small cell lung cancer (a common type of lung cancer). The study aims to see if this combination helps shrink tumors and improve survival.
This trial tests a new combination of two drugs (SKB264 and glecirasib) for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. It aims to see if this combination can shrink tumors or slow their growth.
This trial tests a new combination of two drugs (bempemab and anlotinib) as a first treatment for older adults with advanced lung cancer. The goal is to see if this drug pair can shrink tumors and slow the cancer, possibly without the need for chemo or radiation.
This trial tests a combination of two new drugs (SKB264 and SKB118) for people with a specific type of lung cancer (non-squamous non-small cell) that has an EGFR mutation and has stopped responding to standard EGFR inhibitor treatment. The goal is to see if this combination can shrink tumors or slow their growth.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.